| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
|
31 |
S2 |
p. vii
|
artikel
|
| 2 |
Editorial Board
|
|
|
|
31 |
S2 |
p. i
|
artikel
|
| 3 |
Journal Information
|
|
|
|
31 |
S2 |
p. ii
|
artikel
|
| 4 |
LBA1 Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET)
|
Jhaveri, K.
|
|
|
31 |
S2 |
p. S62
|
artikel
|
| 5 |
96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE
|
Loibl, S.
|
|
|
31 |
S2 |
p. S48
|
artikel
|
| 6 |
138O CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses
|
Jerusalem, G.
|
|
|
31 |
S2 |
p. S63-S64
|
artikel
|
| 7 |
2O ERBB3 mRNA expression in breast cancer (BC): A SOLTI biomarker discovery analysis
|
Pascual, T.
|
|
|
31 |
S2 |
p. S15-S16
|
artikel
|
| 8 |
139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)
|
Dent, R.
|
|
|
31 |
S2 |
p. S64-S65
|
artikel
|
| 9 |
3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer
|
Jacot, W.
|
|
|
31 |
S2 |
p. S16
|
artikel
|
| 10 |
1O Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial
|
Saura, C.
|
|
|
31 |
S2 |
p. S15
|
artikel
|
| 11 |
80O Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+ eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa study
|
O'Shaughnessy, J.
|
|
|
31 |
S2 |
p. S42
|
artikel
|
| 12 |
128O PDL1/CD274 gain/amplification as a predictive marker of checkpoint blockade inhibitor efficacy in metastatic breast cancer: Exploratory analysis of the SAFIR02-IMMUNO randomized phase II trial
|
Bachelot, T.
|
|
|
31 |
S2 |
p. S58-S59
|
artikel
|
| 13 |
97O PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels
|
Hatschek, T.
|
|
|
31 |
S2 |
p. S49
|
artikel
|
| 14 |
98O The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL)
|
Abuhadra, N.
|
|
|
31 |
S2 |
p. S49
|
artikel
|
| 15 |
184O The risk of late breast cancer recurrence in Denmark during 17 years of follow-up
|
Pedersen, R.N.
|
|
|
31 |
S2 |
p. S83
|
artikel
|
| 16 |
137O Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)
|
Curigliano, G.
|
|
|
31 |
S2 |
p. S62-S63
|
artikel
|
| 17 |
127O Tumour mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
|
Karn, T.
|
|
|
31 |
S2 |
p. S58
|
artikel
|
| 18 |
183O Use of physical activity (PA) and supportive care (SC) among patients (pts) with early breast cancer (BC) reporting cancer-related fatigue (CRF)
|
Di Meglio, A.
|
|
|
31 |
S2 |
p. S83
|
artikel
|
| 19 |
140O Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial
|
Ayoub, J-P.
|
|
|
31 |
S2 |
p. S65
|
artikel
|
| 20 |
131P Abrogation of paclitaxel chemo-resistance via epigenetic immune checkpoints regulation in triple negative breast cancer
|
El Shihy, S.A.
|
|
|
31 |
S2 |
p. S59
|
artikel
|
| 21 |
122P A comparison of margin involvement and re-excision rates with the use of ‘Klinitray' versus standard suture specimen orientation in wide local excision surgery for breast cancer
|
Clarke, T.
|
|
|
31 |
S2 |
p. S56
|
artikel
|
| 22 |
84P Actual 5-year survival of dose-dense sequential adjuvant chemotherapy in early breast cancer (BC) patients treated in the post-trastuzumab era: A pooled analysis of 3 clinical trials
|
Aravantinou Fatorou, E.
|
|
|
31 |
S2 |
p. S43
|
artikel
|
| 23 |
82P A multinational study of real-world treatment patterns among patients with early stage HR+/HER2- breast cancer (BC)
|
Criscitiello, C.
|
|
|
31 |
S2 |
p. S42-S43
|
artikel
|
| 24 |
40P Analysis of clinical pathological association with somatic mutations through next-generation sequencing
|
Jung, S.
|
|
|
31 |
S2 |
p. S29
|
artikel
|
| 25 |
47P Androgen receptor expression and survival in triple negative breast cancer
|
Moyano, L.
|
|
|
31 |
S2 |
p. S32
|
artikel
|
| 26 |
171P An outcomes summary of the clinical advances curriculum on CDK4 & 6 inhibition in breast cancer
|
Dorkhom, N.
|
|
|
31 |
S2 |
p. S77
|
artikel
|
| 27 |
37P A pooled analysis of the clinical utility of genomic signatures in young women with breast cancer
|
Ferrigno, A.S.
|
|
|
31 |
S2 |
p. S28
|
artikel
|
| 28 |
164P A prospective approach for the evaluation of a one-step RT-qPCR based test for the quantification of HER2 protein in formalin-fixed and paraffin-embedded breast cancer tissues
|
Al Banyahyati, B.
|
|
|
31 |
S2 |
p. S75
|
artikel
|
| 29 |
48P Association of a genomic index of sensitivity to endocrine therapy with disease-free survival in breast cancer
|
Singh, P.
|
|
|
31 |
S2 |
p. S32
|
artikel
|
| 30 |
99P Association of gut microbiome diversity and composition with pathological complete response (pCR) after neoadjuvant chemotherapy in triple negative breast cancer
|
Vernaci, G.
|
|
|
31 |
S2 |
p. S50
|
artikel
|
| 31 |
166P Awareness and availability of routine germline BRCA1/2 (gBRCA1/2) mutation testing in patients (pts) with advanced breast cancer (ABC) in Germany
|
Lux, M.P.
|
|
|
31 |
S2 |
p. S75-S76
|
artikel
|
| 32 |
41P A window-of-opportunity study with atezolizumab and the oncolityc virus pelareorep in early breast cancer (REO-027, AWARE-1)
|
Manso, L.
|
|
|
31 |
S2 |
p. S30
|
artikel
|
| 33 |
57P Benefit of CDK4/6 inhibitors beyond PIK3CA mutations in metastatic breast cancer patients
|
Tolosa Ortega, P.
|
|
|
31 |
S2 |
p. S35
|
artikel
|
| 34 |
11P BioItaLEE: Comparative biomarker analysis of liquid biopsies and paired tissue samples of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC)
|
Bianchini, G.
|
|
|
31 |
S2 |
p. S20
|
artikel
|
| 35 |
31P BRCA1/2 gene mutation detection in 2686 Chinese clinical samples based on NGS HANDLE technology
|
Zhang, F.
|
|
|
31 |
S2 |
p. S26
|
artikel
|
| 36 |
49P BRCA mutation testing rates among breast cancer patients meeting testing criteria: A single-centre experience
|
Boianu, M.
|
|
|
31 |
S2 |
p. S32
|
artikel
|
| 37 |
25P Breast cancers with heterogeneous HER2 amplification show a diverse distribution of ‘driver’ and ‘passenger’ somatic mutations and copy number variations
|
Van Bockstal, M.R.
|
|
|
31 |
S2 |
p. S25
|
artikel
|
| 38 |
121P Can axillary surgery be avoided in patients with breast pathologic complete response after neoadjuvant systemic therapy? A real-world study in China
|
Chen, R.
|
|
|
31 |
S2 |
p. S56
|
artikel
|
| 39 |
50P Cardiosafe nano-formulation of doxorubicin allows coadministration with trastuzumab in neoadjuvant setting improving antitumor efficacy and preventing trastuzumab-mediated cardiotoxicity in HER2 + murine model of breast cancer
|
Mazzucchelli, S.
|
|
|
31 |
S2 |
p. S33
|
artikel
|
| 40 |
52P Characterising clinicopathological and biological parameters predictive of outcome for patients diagnosed with invasive lobular carcinoma
|
Simpson, P.
|
|
|
31 |
S2 |
p. S33
|
artikel
|
| 41 |
8P Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT)
|
Griguolo, G.
|
|
|
31 |
S2 |
p. S19
|
artikel
|
| 42 |
45P Characterizing the impact of pathogenic BRCA mutations on tissue-specific gene expression and pre-mRNA splicing
|
Bak-Gordon, P.
|
|
|
31 |
S2 |
p. S31
|
artikel
|
| 43 |
6P Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER+/HER2-negative advanced breast cancer (ABC)
|
Galardi, F.
|
|
|
31 |
S2 |
p. S18
|
artikel
|
| 44 |
5P Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i)
|
Martínez-Sáez, O.
|
|
|
31 |
S2 |
p. S17
|
artikel
|
| 45 |
93P Clinical and genetic predictions of early-onset cardiac toxicity in adjuvant chemotherapy for breast cancer
|
Liu, B.
|
|
|
31 |
S2 |
p. S46
|
artikel
|
| 46 |
75P Clinical and pathological feature of primary lung cancer in patients with primary breast cancer
|
Zeng, T.
|
|
|
31 |
S2 |
p. S40
|
artikel
|
| 47 |
173P Clinical characteristics of long-term responders to anti-HER2 therapy in metastatic breast cancer: A review of the charactHER clinical data
|
Skrobo, D.
|
|
|
31 |
S2 |
p. S78
|
artikel
|
| 48 |
153P Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials
|
Franzoi, M.A.
|
|
|
31 |
S2 |
p. S71
|
artikel
|
| 49 |
23P Clinical, pathological and gene expression features of HER2-low breast cancer
|
Schettini, F.
|
|
|
31 |
S2 |
p. S24
|
artikel
|
| 50 |
74P Clinical value of HER3/ErbB3 serum level determination in patients with breast cancer qualified for neoadjuvant chemotherapy
|
Kotowicz, B.
|
|
|
31 |
S2 |
p. S40
|
artikel
|
| 51 |
198P Comparative study between the clinical effect of palonosetron and granisetron as antiemetic therapy for patients receiving highly emetogenic chemotherapy regimens
|
Mahrous, M.A.
|
|
|
31 |
S2 |
p. S86-S87
|
artikel
|
| 52 |
34P Comprehensive clinical and molecular portraits of grade 3 ER+ HER- breast cancer
|
Wang, K.
|
|
|
31 |
S2 |
p. S27
|
artikel
|
| 53 |
64P Comprehensive genomic analysis of primary triple negative breast cancer prior to neoadjuvant chemotherapy
|
Drobniene, M.
|
|
|
31 |
S2 |
p. S36-S37
|
artikel
|
| 54 |
123P Cosmetic outcome after vacuum-assisted excision is good and independent of the amount of resected tissue
|
Van De Voort, E.
|
|
|
31 |
S2 |
p. S56-S57
|
artikel
|
| 55 |
104P Cost and healthcare resource utilization (HCRU) for patients receiving neoadjuvant therapy for early-stage triple-negative breast cancer (ESTNBC)
|
Rhodes, W.C.
|
|
|
31 |
S2 |
p. S51
|
artikel
|
| 56 |
68P Deciphering the interplay between nuclear RNA export factors and long non-coding RNAs in breast cancer metabolism
|
Klec, C.
|
|
|
31 |
S2 |
p. S38
|
artikel
|
| 57 |
58P Detection of PIK3CA mutations in plasma ctDNA by Crystal Digital PCR for the selection of alpelisib treatment in routine clinical practice in advanced breast cancer patients
|
de La Motte Rouge, T.
|
|
|
31 |
S2 |
p. S35
|
artikel
|
| 58 |
168P Development of a combined clinical model to predict progression-free survival (PFS) in advanced breast cancer (ABC) treated with CDK4/6 inhibitors (CDK4/6i)
|
Martínez-Sáez, O.
|
|
|
31 |
S2 |
p. S76
|
artikel
|
| 59 |
67P Digital analysis of distant and cancer-associated adipocytes in breast cancer
|
Isnaldi, E.
|
|
|
31 |
S2 |
p. S37-S38
|
artikel
|
| 60 |
17P Dysregulation of immune checkpoint proteins in newly diagnosed early breast cancer patients
|
Rapoport, B.
|
|
|
31 |
S2 |
p. S22
|
artikel
|
| 61 |
150P Eligibility of real-world patients with metastatic breast cancer in clinical trials
|
Batra, A.
|
|
|
31 |
S2 |
p. S70
|
artikel
|
| 62 |
197P Epirubicin-induced cardiotoxicity: Use of myocardial strain for early detection of left ventricular dysfunction before LVEF declines
|
Ben Abdallah, I.
|
|
|
31 |
S2 |
p. S86
|
artikel
|
| 63 |
54P Establishment and characterization of luminal A breast PDX models from patients with acquired resistance to CDK 4/6 inhibitors
|
Wick, M.J.
|
|
|
31 |
S2 |
p. S34
|
artikel
|
| 64 |
28P Europe-side external quality assessment (EQA) of RNA based testing of ER, PR, HER2 and Ki67 in invasive breast cancer
|
Erber, R.
|
|
|
31 |
S2 |
p. S25
|
artikel
|
| 65 |
111P Evaluating the protective effect of metformine on cancer: A retrospective cohort analysis
|
Honoré, N.
|
|
|
31 |
S2 |
p. S53
|
artikel
|
| 66 |
14P Evolution of cytotoxic and regulatory T cells in blood and in tissue after neoadjuvant treatment in breast carcinoma
|
Palazón Carrión, N.
|
|
|
31 |
S2 |
p. S21-S22
|
artikel
|
| 67 |
51P Evolution of low HER2 expressions between primary and metastatic breast cancer
|
Tarantino, P.
|
|
|
31 |
S2 |
p. S33
|
artikel
|
| 68 |
42P Expression of WNT, Hedgehog and NOTCH signaling pathways in HER-2 overexpressed and triple negative subtypes of breast cancer with high and low content of cancer stem cells
|
Demidov, S.
|
|
|
31 |
S2 |
p. S30
|
artikel
|
| 69 |
115P Factors associated with mastectomy in women with small residual tumour after neoadjuvant chemotherapy for breast cancer
|
Bernell, E.
|
|
|
31 |
S2 |
p. S54
|
artikel
|
| 70 |
170P 18F-FDG PET/CT features of the metastases from intrinsic NSIBC molecular types and its prognostic value
|
Xu, M.
|
|
|
31 |
S2 |
p. S77
|
artikel
|
| 71 |
194P Follow up after breast cancer in real life
|
Zaluska-Kusz, J.
|
|
|
31 |
S2 |
p. S86
|
artikel
|
| 72 |
12P Gene expression profiling in early breast cancer treated with neoadjuvant ribociclib plus letrozole (R+L) versus chemotherapy (CT): A correlative analysis of the SOLTI-1402/CORALLEEN phase II trial
|
Chic, N.
|
|
|
31 |
S2 |
p. S21
|
artikel
|
| 73 |
91P Gene expression profiling in localised luminal N+ breast cancer: Efficacy and utility of 50 gene expression platform in adjuvant treatment decision making
|
Tolosa Ortega, P.
|
|
|
31 |
S2 |
p. S46
|
artikel
|
| 74 |
70P Genetic polymorphisms of ESR1 are associated with hormone resistance to aromatase inhibitors therapy in patients with metastatic luminal breast cancer (MLBC)
|
Tarasenko, T.
|
|
|
31 |
S2 |
p. S38
|
artikel
|
| 75 |
21P Germline and somatic variants in DNA DMAGE repair (DDR) genes in patients with untreated, early-stage triple negative breast cancers (TNBC)
|
Litton, J.K.
|
|
|
31 |
S2 |
p. S23-S24
|
artikel
|
| 76 |
157P Germline BRCA1/2 (gBRCA1/2) testing patterns among oncologists (ONC) treating HER2- advanced breast cancer (ABC): Results from a multi-country real-world study
|
Mahtani, R.
|
|
|
31 |
S2 |
p. S72-S73
|
artikel
|
| 77 |
13P HER2 low testing in breast cancer: How to optimize detection
|
Cecchi, F.
|
|
|
31 |
S2 |
p. S21
|
artikel
|
| 78 |
33P Immune analysis of lymph nodes in relation to the presence or absence of tumour infiltrating lymphocytes in triple negative breast cancers
|
Quintana, A.
|
|
|
31 |
S2 |
p. S27
|
artikel
|
| 79 |
165P Immune characterization of the de novo oligometastatic breast cancer
|
Chretien, S.
|
|
|
31 |
S2 |
p. S75
|
artikel
|
| 80 |
66P Impact of EPClin on adjuvant therapeutic decision-making and comparison of EPClin to PREDICT tool
|
Bourien, H.
|
|
|
31 |
S2 |
p. S37
|
artikel
|
| 81 |
188P Impact of HIV infection (HIV+) on baseline characteristics and survival of breast cancer (BC) patients (pts): A systematic review and meta-analysis
|
Brandão, M.D.R.A.
|
|
|
31 |
S2 |
p. S84-S85
|
artikel
|
| 82 |
113P Impact of local recurrence on disease-specific survival in breast cancer patients who underwent breast-conserving surgery
|
Tiezzi, D.G.
|
|
|
31 |
S2 |
p. S54
|
artikel
|
| 83 |
141P Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer
|
Schmid, P.
|
|
|
31 |
S2 |
p. S65-S66
|
artikel
|
| 84 |
83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes
|
Martin Jimenez, M.
|
|
|
31 |
S2 |
p. S43
|
artikel
|
| 85 |
4P Independent validation of the PAM50-based chemoendocrine score (CES) as pathologic complete response (pCR) and disease-free survival (DFS) predictor in hormone receptor (HR)+/HER2+ breast cancer (BC)
|
Pascual, T.
|
|
|
31 |
S2 |
p. S17
|
artikel
|
| 86 |
30P In search of a bone metastasis (BM) gene signature in circulating tumour cells (CTCs) from stage IV breast cancer (BC) patients
|
D'Oronzo, S.
|
|
|
31 |
S2 |
p. S26
|
artikel
|
| 87 |
94P Integration of clinicopathological and genomic data and adjuvant treatment decisions in premenopausal women with recurrence scores between 16 and 25
|
Alsendi, M.E.
|
|
|
31 |
S2 |
p. S46-S47
|
artikel
|
| 88 |
18P Inter-tumour heterogeneity in breast cancers: The dynamic evolution of cancer genome during the metastatic process
|
Fumagalli, C.
|
|
|
31 |
S2 |
p. S23
|
artikel
|
| 89 |
65P Investigating the molecular connection between hormone receptor status and ploidy management in breast cancer
|
Nath, S.
|
|
|
31 |
S2 |
p. S37
|
artikel
|
| 90 |
116P Is young age an independent adverse prognostic factor in carcinoma breast? A single institute retrospective comparative study from South India
|
K P, A.
|
|
|
31 |
S2 |
p. S55
|
artikel
|
| 91 |
29P Key cancer gene expression features of hereditary breast cancer in the Kazakh population
|
Omarbayeva, N.
|
|
|
31 |
S2 |
p. S25-S26
|
artikel
|
| 92 |
88P Latent class analysis (LCA) to identify and describe clinically relevant subgroups in a multinational study of patients with HR+/HER2- early breast cancer (eBC)
|
Rider, A.
|
|
|
31 |
S2 |
p. S45
|
artikel
|
| 93 |
79P Liquid biopsy-based detection of PIK3Ca mutations in HR positive metastastic breast cancer patients
|
Suppan, C.
|
|
|
31 |
S2 |
p. S41
|
artikel
|
| 94 |
103P Loss of HER2 after neoadjuvant treatment of HER2+ early breast cancer
|
Morales, S.
|
|
|
31 |
S2 |
p. S51
|
artikel
|
| 95 |
105P Lower-dose apatinib combined with nanoparticle albumin-bound paclitaxel and carboplatin as a neoadjuvant regimen for triple negative breast cancer: A prospective, single-arm, phase II study
|
Yin, Y.
|
|
|
31 |
S2 |
p. S52
|
artikel
|
| 96 |
132P MALAT-1 ruling the miR-182/PIG-C/MSLN triad in triple negative breast cancer
|
Samir, A.
|
|
|
31 |
S2 |
p. S59-S60
|
artikel
|
| 97 |
156P Matching-adjusted indirect comparison (MAIC) of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2 ABC)
|
Rugo, H.S.
|
|
|
31 |
S2 |
p. S72
|
artikel
|
| 98 |
196P Menopausal symptoms in premenopausal patients with luminal early breast cancer developing chemotherapy-induced amenorrhea
|
Zribi, A.
|
|
|
31 |
S2 |
p. S86
|
artikel
|
| 99 |
73P microRNA expression profiles of single hormone receptor-positive breast cancers
|
Kunc, M.
|
|
|
31 |
S2 |
p. S39-S40
|
artikel
|
| 100 |
36P Molecular subtypes in Tunisian breast cancer
|
Frikha, M.
|
|
|
31 |
S2 |
p. S28
|
artikel
|
| 101 |
38P Morphological heterogeneity in ductal carcinoma in situ of the breast
|
Stanciu Pop, C.
|
|
|
31 |
S2 |
p. S28-S29
|
artikel
|
| 102 |
72P Non-mass like enhancement patterns on MR mammography and their pathological correlation
|
Parashar, A.
|
|
|
31 |
S2 |
p. S39
|
artikel
|
| 103 |
114P Non-metastatic metaplastic breast cancer; clinicopathological characteristics and treatment outcomes: A single institution experience
|
Erjan, A.A.
|
|
|
31 |
S2 |
p. S54
|
artikel
|
| 104 |
44P Obesity is associated with a late-stage diagnosis in triple-negative breast cancer
|
Aranda-Gutierrez, A.
|
|
|
31 |
S2 |
p. S31
|
artikel
|
| 105 |
174P Occurrence of brain metastasis and treatment patterns among patients with HER2-positive metastatic breast cancer
|
Vidal, G.A.
|
|
|
31 |
S2 |
p. S78
|
artikel
|
| 106 |
162P Overcoming resistance to endocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: A meta-analysis of randomized clinical trials
|
Zhu, W.
|
|
|
31 |
S2 |
p. S74
|
artikel
|
| 107 |
158P Patient (pt) demographics, treatment patterns (tx) and hematologic (heme) toxicities among pts with HER2− advanced breast cancer (ABC) and BRCA1/2 mutation(s) (BRCA1/2mut): A multi-country real-world (RW) study
|
Mahtani, R.
|
|
|
31 |
S2 |
p. S73
|
artikel
|
| 108 |
87P Patient-reported and cancer-specific health-related quality of life among patients with early stage HR+/HER2- breast cancer (BC)
|
Criscitiello, C.
|
|
|
31 |
S2 |
p. S44-S45
|
artikel
|
| 109 |
90P Patient-reported outcomes among patients with HR+/HER2- early breast cancer: A systematic literature review
|
Salvo, E.M.
|
|
|
31 |
S2 |
p. S45-S46
|
artikel
|
| 110 |
187P Patient-reported outcomes near end-of-life in patients with breast cancer
|
Batra, A.
|
|
|
31 |
S2 |
p. S84
|
artikel
|
| 111 |
144P Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3)
|
Fasching, P.
|
|
|
31 |
S2 |
p. S67-S68
|
artikel
|
| 112 |
86P Patients (pts) preference for different administration methods of trastuzumab (T) in pts with HER2+ early breast cancer (BC) treated within the GAIN-2 trial
|
Reinisch, M.
|
|
|
31 |
S2 |
p. S44
|
artikel
|
| 113 |
43P PDL1 protein expression is a prognostic factor in triple negative breast cancer
|
Yue, J.
|
|
|
31 |
S2 |
p. S30-S31
|
artikel
|
| 114 |
147P Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan (T-DXd) with OATP1B/CYP3A inhibitors in patients with HER2-expressing advanced solid tumours
|
Takahashi, M.
|
|
|
31 |
S2 |
p. S68-S69
|
artikel
|
| 115 |
129P Phase II study of pembrolizumab and nab-paclitaxel in HER2-negative metastatic breast cancer: Hormone receptor-positive cohort
|
Novik, Y.
|
|
|
31 |
S2 |
p. S59
|
artikel
|
| 116 |
190P Phyllodes tumour of the breast: 10 years of experience in a Mexican oncology reference center
|
Contreras Salcido, M.I.
|
|
|
31 |
S2 |
p. S85
|
artikel
|
| 117 |
19P PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study
|
Guarneri, V.
|
|
|
31 |
S2 |
p. S23
|
artikel
|
| 118 |
163P Population-adjusted comparison of SOLAR-1 and BOLERO-2: PFS with second-line alpelisib + fulvestrant vs everolimus + exemestane in postmenopausal pts with PIK3CA-mut hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC)
|
Ciruelos, E.M.
|
|
|
31 |
S2 |
p. S74
|
artikel
|
| 119 |
149P Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry: Comparison of three different prognostic scores
|
Riecke, K.
|
|
|
31 |
S2 |
p. S70
|
artikel
|
| 120 |
10P Prediction of the 21-gene recurrence score by a non-genomic approach in stage I estrogen receptor-positive, HER2-negative breast cancer
|
Le Du, F.
|
|
|
31 |
S2 |
p. S19-S20
|
artikel
|
| 121 |
102P Predictive models associated with the presence of pathological complete response following neoadjuvant chemotherapy for breast cancer
|
Xie, Y.
|
|
|
31 |
S2 |
p. S51
|
artikel
|
| 122 |
101P Predictors of 18F-fluorodeoxyglucose (F) positron-emission tomography (PET)-driven disease detection in patients (pts) with HER2[+] early breast cancer (EBC). A substudy of the PHERGain trial
|
Llombart Cussac, A.
|
|
|
31 |
S2 |
p. S50
|
artikel
|
| 123 |
117P Pregnancy-associated breast cancer (PABC): Demographics and outcome analysis from a lower and middle income country (LMIC)
|
Bajpai, J.
|
|
|
31 |
S2 |
p. S55
|
artikel
|
| 124 |
107P Preservation of ovarian function with goserelin in young breast cancer patients: Does it hamper the effect of neoadjuvant chemotherapy?
|
Wang, S.Y.
|
|
|
31 |
S2 |
p. S52
|
artikel
|
| 125 |
110P Primary endocrine therapy of breast cancer: Is there a good radiological technique to define pathological response?
|
Lopez Velazco, J.I.
|
|
|
31 |
S2 |
p. S52-S53
|
artikel
|
| 126 |
59P Primary tumour and circulating tumour cell (CTC) copy number alterations (CNAs) in triple negative breast cancer (TNBC) patients (pts) treated with neoadjuvant chemotherapy (NAC)
|
Di Cosimo, S.
|
|
|
31 |
S2 |
p. S35-S36
|
artikel
|
| 127 |
60P Prognosis and survival of single hormone receptor positive breast cancer comparing to double HR positive and triple-negative breast cancers
|
Oualla, K.
|
|
|
31 |
S2 |
p. S36
|
artikel
|
| 128 |
125P Prognostic factors in phyllodes tumours (PT) of the breast: A single-institution cohort
|
Di Liso, E.
|
|
|
31 |
S2 |
p. S57
|
artikel
|
| 129 |
7P Prognostic value of the immune infiltration score in early breast cancer patients receiving dual HER2 blockade with trastuzumab and pertuzumab: An exploratory analysis of a randomized clinical trial
|
Wan, G.
|
|
|
31 |
S2 |
p. S18
|
artikel
|
| 130 |
155P Prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients
|
Montagna, E.
|
|
|
31 |
S2 |
p. S72
|
artikel
|
| 131 |
142P Quality-adjusted survival with ribociclib plus fulvestrant (R+F) versus placebo plus fulvestrant (P+F) in postmenopausal women (PMW) HR+/HER2- advanced breast cancer (ABC) based on the MONALEESA-3 trial
|
Jerusalem, G.
|
|
|
31 |
S2 |
p. S66
|
artikel
|
| 132 |
143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study
|
Kahan, Z.
|
|
|
31 |
S2 |
p. S66-S67
|
artikel
|
| 133 |
85P Racial differences in predictive value of 21-gene recurrence score assay: A population-based study using the SEER database
|
Jung, J.
|
|
|
31 |
S2 |
p. S44
|
artikel
|
| 134 |
172P REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC)
|
Singer, C.F.
|
|
|
31 |
S2 |
p. S77-S78
|
artikel
|
| 135 |
175P Real-world patient and practice characteristics associated with use of CDK4/6 inhibitors among patients receiving first therapy for HR+/HER2- advanced or metastatic breast cancer in Italy and Germany
|
de Placido, S.
|
|
|
31 |
S2 |
p. S79
|
artikel
|
| 136 |
177P Real world treatment patterns and clinical outcomes associated with palbociclib combination therapy in Germany: Results from the IRIS study
|
Taylor-Stokes, G.
|
|
|
31 |
S2 |
p. S79-S80
|
artikel
|
| 137 |
176P Real-world tumour response of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US clinical practices
|
Brufsky, A.
|
|
|
31 |
S2 |
p. S79
|
artikel
|
| 138 |
189P Recommendation for “a start to move” program: A 8-week program of incremental physical activity in sedentary breast cancer survivors
|
Mazzocco, K.
|
|
|
31 |
S2 |
p. S85
|
artikel
|
| 139 |
76P Retrospective study about the prevalence of (TILs) tumour infiltrating lymphocytes in non-metastatic triple negative breast cancer patients and its prognostic value
|
Kamal, A.M.
|
|
|
31 |
S2 |
p. S40-S41
|
artikel
|
| 140 |
178P Risks of distant metastasis of different breast cancer subtypes after surgery: A cohort study in indigenous Indonesian population
|
Sakti, H.L.
|
|
|
31 |
S2 |
p. S80
|
artikel
|
| 141 |
39P Role of early circulating tumour cell (CTC) monitoring for prediction of clinical outcome in patients with HER-2 negative metastatic breast cancer receiving first-line treatment with bevacizumab and paclitaxel
|
Álvarez-López, I.
|
|
|
31 |
S2 |
p. S29
|
artikel
|
| 142 |
53P Role of immune biomarkers in evaluating predictive and prognostic value in advanced stage HER2 positive breast cancer
|
Pasricha, S.
|
|
|
31 |
S2 |
p. S34
|
artikel
|
| 143 |
109P Role of MRI and histopathological classification in pre-treatment identification of non-responders to neoadjuvant chemotherapy in breast cancer
|
Vertakova Krakovska, B.
|
|
|
31 |
S2 |
p. S52
|
artikel
|
| 144 |
55P Role of radiomics for predicting immunophenotypes in male breast cancer
|
Koyyala, V.P.B.
|
|
|
31 |
S2 |
p. S34
|
artikel
|
| 145 |
71P Role of radiomics in predicting molecular phenotypes of female breast cancer
|
Jajodia, A.
|
|
|
31 |
S2 |
p. S39
|
artikel
|
| 146 |
146P Safety and metabolic effects of fasting-mimicking diet in breast cancer patients
|
Vernieri, C.
|
|
|
31 |
S2 |
p. S68
|
artikel
|
| 147 |
118P Should DIBH (deep inspiration breath-hold) be the standard of care in LBC (left breast cancer)?
|
Garcia Alvarez, M.G.
|
|
|
31 |
S2 |
p. S55
|
artikel
|
| 148 |
192P Strategies and results of oncofertility counselling in young breast cancer patients
|
Kufel-Grabowska, J.
|
|
|
31 |
S2 |
p. S85
|
artikel
|
| 149 |
63P Study of single nucleotide polymorphism of thymocyte selection associated high mobility group box 3 and fibroblast growth factor receptor 2 genes in breast cancer patients
|
Alhanafy, A.M.
|
|
|
31 |
S2 |
p. S36
|
artikel
|
| 150 |
148P Surgery (Sx) of the primary tumour in de novo metastatic breast cancer (BC) patients (pts) is associated with increased survival: A nationwide population-based study by the Belgian Cancer Registry (BCR) and the Belgian Society of Medical Oncology (BSMO)
|
Brandão, M.D.R.A.
|
|
|
31 |
S2 |
p. S69
|
artikel
|
| 151 |
154P Survival outcome of indigenous and non-indigenous women of Western Australia with breast cancer in relation to remoteness
|
Khan, A.
|
|
|
31 |
S2 |
p. S71
|
artikel
|
| 152 |
120P Synchronous breast cancers with dissimilar radiological appearances
|
Gnaneswaran, S.
|
|
|
31 |
S2 |
p. S56
|
artikel
|
| 153 |
89P Tamoxifen versus aromatase inhibitors as adjuvant therapy in premenopausal women with hormone receptor-positive breast cancer: Effects on sexuality and the female reproductive system
|
Skolariki, A.
|
|
|
31 |
S2 |
p. S45
|
artikel
|
| 154 |
69P TGFBI promoter methylation validation as an epigenetic biomarker for trastuzumab resistance in HER2+ breast cancer patients cohort
|
Pla, H.
|
|
|
31 |
S2 |
p. S38
|
artikel
|
| 155 |
15P The CelTIL score as an early predictor of anti-tumour response following neoadjuvant therapy (NAT): A SOLTI biomarker analysis
|
González-Farré, B.
|
|
|
31 |
S2 |
p. S22
|
artikel
|
| 156 |
159P The clinical landscape of central nervous system (CNS) involvement in metastatic triple-negative breast cancer (TNBC) patients (pts)
|
Eiger, D.
|
|
|
31 |
S2 |
p. S73-S74
|
artikel
|
| 157 |
9P The histopathologic profile of pregnancy associated breast cancer; a particularly aggressive breast cancer subtype. Analysis of the Dutch National Registry
|
Suelmann, B.
|
|
|
31 |
S2 |
p. S19
|
artikel
|
| 158 |
24P The influence of metabolic syndrome on the risk of breast cancer: A study analysing nationwide data from the Korean National Health Insurance Service
|
Hwang, K-T.
|
|
|
31 |
S2 |
p. S24
|
artikel
|
| 159 |
151P The landscape of patients with metastatic breast cancer enrolled in phase I trials
|
Marra,
|
|
|
31 |
S2 |
p. S70-S71
|
artikel
|
| 160 |
32P The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of CDK 4/6 inhibitors in women with hormone receptor-positive/HER2-negative advanced breast cancer
|
Zattarin, E.
|
|
|
31 |
S2 |
p. S26-S27
|
artikel
|
| 161 |
35P The role of interplay between microRNA-133a and Mre11 in breast cancer
|
Kao, L.C.
|
|
|
31 |
S2 |
p. S28
|
artikel
|
| 162 |
169P Trastuzumab use among patients with HER2-positive metastatic breast cancer in an electronic health records database
|
Lindegger, N.
|
|
|
31 |
S2 |
p. S76-S77
|
artikel
|
| 163 |
167P TRIP13 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse
|
Du, Z.
|
|
|
31 |
S2 |
p. S76
|
artikel
|
| 164 |
46P Tumour infiltrating lymphocytes in breast cancer: High levels of CD3, CD8 cells and Immunoscore® are associated with pathological CR in patients receiving neo-adjuvant chemotherapy
|
Rapoport, B.L.
|
|
|
31 |
S2 |
p. S31-S32
|
artikel
|
| 165 |
186P Using a new controlled thermotherapy (Hilotherapy®) during chemotherapy prevents chemotherapy induced polyneuropathy (CIPN)
|
Schaper, T.
|
|
|
31 |
S2 |
p. S83-S84
|
artikel
|
| 166 |
62P XRCC1 (Arg194Trp), Palb2 T1100T (3300T>G), HMMR (V353A), TNF (aG308A) polymorphisms as diagnostic markers of breast cancer in the Kyrgyz ethnic group
|
Semetei kyzy, A.
|
|
|
31 |
S2 |
p. S36
|
artikel
|
| 167 |
Society Pages
|
|
|
|
31 |
S2 |
p. v-vi
|
artikel
|
| 168 |
Table of Contents
|
|
|
|
31 |
S2 |
p. iv
|
artikel
|
| 169 |
134TiP A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2− primary breast cancer: CheckMate 7FL
|
Curigliano, G.
|
|
|
31 |
S2 |
p. S60-S61
|
artikel
|
| 170 |
133TiP A phase II trial of nivolumab + palbociclib + anastrozole in postmenopausal women with ER+/HER2– primary breast cancer: CheckMate 7A8
|
Tolaney, S.M.
|
|
|
31 |
S2 |
p. S60
|
artikel
|
| 171 |
199TiP A single-arm, open label, single center study to evaluate the safety and clinical outcome of using FR-Mask in breast cancer patients with radiation-irritated skin
|
Chu, C-N.
|
|
|
31 |
S2 |
p. S87
|
artikel
|
| 172 |
182TiP Effectiveness of niraparib plus aromatase inhibitors (AI) for germinal BRCA1/2-mutated (gBRCAm) or homologous recombination deficient (HRD), hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer (ABC). The LUZERN Strategy
|
Blanch, S.
|
|
|
31 |
S2 |
p. S82
|
artikel
|
| 173 |
179TiP EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine therapy for ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy
|
Bardia, A.
|
|
|
31 |
S2 |
p. S80
|
artikel
|
| 174 |
135TiP GELATO-trial: Assessing the efficacy of carboplatin and atezolizumab in metastatic lobular breast cancer
|
Voorwerk, L.
|
|
|
31 |
S2 |
p. S61
|
artikel
|
| 175 |
95TiP Gruppo Italiano Mammella (GIM) 10 – CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR+) early breast cancer (EBC)
|
Lambertini, M.
|
|
|
31 |
S2 |
p. S47
|
artikel
|
| 176 |
180TiP Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial
|
Ciruelos, E.M.
|
|
|
31 |
S2 |
p. S80-S81
|
artikel
|
| 177 |
112TiP SOLTI-1710 PROMETEO II: Palbociclib in combination with letrozole in patients with hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)
|
Ciruelos, E.M.
|
|
|
31 |
S2 |
p. S53
|
artikel
|
| 178 |
126TiP Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (SAKK 23/16 / IBCSG 57-18 / ABCSG-53 / GBG 101 - TAXIS): A multicenter randomized phase III trial
|
Weber, W.P.
|
|
|
31 |
S2 |
p. S57
|
artikel
|
| 179 |
181TiP Xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement (XENERA™-1)
|
Schmid, P.
|
|
|
31 |
S2 |
p. S81
|
artikel
|
Tijdschrift beschrijving